{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T01:03:53Z","timestamp":1793149433691,"version":"4.5.0"},"reference-count":181,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T00:00:00Z","timestamp":1675900800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Neurol"],"DOI":"10.1038\/s41582-023-00775-5","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T21:06:06Z","timestamp":1675976766000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":165,"title":["Epstein\u2013Barr virus as a leading cause of multiple sclerosis: mechanisms and implications"],"prefix":"10.1038","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2892-6986","authenticated-orcid":false,"given":"Kjetil","family":"Bjornevik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6419-1940","authenticated-orcid":false,"given":"Christian","family":"M\u00fcnz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey I.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0585-3294","authenticated-orcid":false,"given":"Alberto","family":"Ascherio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,2,9]]},"reference":[{"key":"775_CR1","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1136\/bmj.325.7373.1128","volume":"325","author":"J Murray","year":"2002","unstructured":"Murray, J. Infection as a cause of multiple sclerosis. BMJ 325, 1128 (2002).","journal-title":"BMJ"},{"key":"775_CR2","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/archneur.55.3.421","volume":"55","author":"SD Cook","year":"1998","unstructured":"Cook, S. D. Multiple sclerosis. Arch. Neurol. 55, 421\u2013423 (1998).","journal-title":"Arch. Neurol."},{"key":"775_CR3","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1001\/archneur.1966.00470080097015","volume":"14","author":"JF Kurtzke","year":"1966","unstructured":"Kurtzke, J. F. An epidemiologic approach to multiple sclerosis. Arch. Neurol. 14, 213\u2013222 (1966).","journal-title":"Arch. Neurol."},{"key":"775_CR4","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0301-0082(95)80008-V","volume":"47","author":"CR Gale","year":"1995","unstructured":"Gale, C. R. & Martyn, C. N. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47, 425\u2013448 (1995).","journal-title":"Prog. Neurobiol."},{"key":"775_CR5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0895-4356(00)00268-7","volume":"54","author":"JF Kurtzke","year":"2001","unstructured":"Kurtzke, J. F. & Heltberg, A. Multiple sclerosis in the Faroe Islands: an epitome. J. Clin. Epidemiol. 54, 1\u201322 (2001).","journal-title":"J. Clin. Epidemiol."},{"key":"775_CR6","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1212\/WNL.32.2.143","volume":"32","author":"JF Kurtzke","year":"1982","unstructured":"Kurtzke, J. F., Gudmundsson, K. R. & Bergmann, S. Multiple sclerosis in Iceland: 1. Evidence of a postwar epidemic. Neurology 32, 143\u2013150 (1982).","journal-title":"Neurology"},{"key":"775_CR7","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1136\/jech.34.4.229","volume":"34","author":"DC Poskanzer","year":"1980","unstructured":"Poskanzer, D. C., Prenney, L. B., Sheridan, J. L. & Kondy, J. Y. Multiple sclerosis in the Orkney and Shetland Islands. I: Epidemiology, clinical factors, and methodology. J. Epidemiol. Commun. Health 34, 229\u2013239 (1980).","journal-title":"J. Epidemiol. Commun. Health"},{"key":"775_CR8","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1001\/archneur.1983.04050070036006","volume":"40","author":"PF Bray","year":"1983","unstructured":"Bray, P. F., Bloomer, L. C., Salmon, V. C., Bagley, M. H. & Larsen, P. D. Epstein\u2013Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch. Neurol. 40, 406\u2013408 (1983).","journal-title":"Arch. Neurol."},{"key":"775_CR9","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1212\/WNL.35.3.435","volume":"35","author":"PD Larsen","year":"1985","unstructured":"Larsen, P. D., Bloomer, L. C. & Bray, P. F. Epstein\u2013Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 35, 435\u2013438 (1985).","journal-title":"Neurology"},{"key":"775_CR10","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1001\/archneur.1980.00500510052009","volume":"37","author":"CV Sumaya","year":"1980","unstructured":"Sumaya, C. V., Myers, L. W. & Ellison, G. W. Epstein\u2013Barr virus antibodies in multiple sclerosis. Arch. Neurol. 37, 94\u201396 (1980).","journal-title":"Arch. Neurol."},{"key":"775_CR11","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/ana.20820","volume":"59","author":"EL Thacker","year":"2006","unstructured":"Thacker, E. L., Mirzaei, F. & Ascherio, A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59, 499\u2013503 (2006).","journal-title":"Ann. Neurol."},{"key":"775_CR12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1001\/archneur.63.6.noc50328","volume":"63","author":"GN DeLorenze","year":"2006","unstructured":"DeLorenze, G. N. et al. Epstein\u2013Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63, 839\u2013844 (2006).","journal-title":"Arch. Neurol."},{"key":"775_CR13","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1001\/jama.293.20.2496","volume":"293","author":"LI Levin","year":"2005","unstructured":"Levin, L. I. et al. Temporal relationship between elevation of Epstein\u2013Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496\u20132500 (2005).","journal-title":"JAMA"},{"key":"775_CR14","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1177\/1352458511408991","volume":"17","author":"KL Munger","year":"2011","unstructured":"Munger, K. L., Levin, L. I., O\u2019Reilly, E. J., Falk, K. I. & Ascherio, A. Anti-Epstein\u2013Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel. Mult. Scler. 17, 1185\u20131193 (2011).","journal-title":"Mult. Scler."},{"key":"775_CR15","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1212\/01.WNL.0000130496.51156.D7","volume":"62","author":"P Sundstrom","year":"2004","unstructured":"Sundstrom, P. et al. An altered immune response to Epstein\u2013Barr virus in multiple sclerosis: a prospective study. Neurology 62, 2277\u20132282 (2004).","journal-title":"Neurology"},{"key":"775_CR16","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/archneur.64.1.72","volume":"64","author":"TR Nielsen","year":"2007","unstructured":"Nielsen, T. R. et al. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 64, 72\u201375 (2007).","journal-title":"Arch. Neurol."},{"key":"775_CR17","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1177\/1352458520907901","volume":"26","author":"BM Jacobs","year":"2020","unstructured":"Jacobs, B. M., Giovannoni, G., Cuzick, J. & Dobson, R. Systematic review and meta-analysis of the association between Epstein\u2013Barr virus, multiple sclerosis and other risk factors. Mult. Scler. 26, 1281\u20131297 (2020).","journal-title":"Mult. Scler."},{"key":"775_CR18","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000318","volume":"4","author":"R Dobson","year":"2017","unstructured":"Dobson, R., Kuhle, J., Middeldorp, J. & Giovannoni, G. Epstein\u2013Barr-negative MS: a true phenomenon? Neurol. Neuroimmunol. Neuroinflamm. 4, e318 (2017).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"775_CR19","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1136\/jnnp-2020-322941","volume":"91","author":"S Abrahamyan","year":"2020","unstructured":"Abrahamyan, S. et al. Complete Epstein\u2013Barr virus seropositivity in a large cohort of patients with early multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 91, 681\u2013686 (2020).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"775_CR20","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1126\/science.abj8222","volume":"375","author":"K Bjornevik","year":"2022","unstructured":"Bjornevik, K. et al. Longitudinal analysis reveals high prevalence of Epstein\u2013Barr virus associated with multiple sclerosis. Science 375, 296\u2013301 (2022).","journal-title":"Science"},{"key":"775_CR21","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/bjs.18004619704","volume":"46","author":"D Burkitt","year":"1958","unstructured":"Burkitt, D. A sarcoma involving the jaws in African children. Br. J. Surg. 46, 218\u2013223 (1958).","journal-title":"Br. J. Surg."},{"key":"775_CR22","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S0140-6736(64)91524-7","volume":"1","author":"MA Epstein","year":"1964","unstructured":"Epstein, M. A., Achong, B. G. & Barr, Y. M. Virus particles in cultured lymphoblasts from Burkitt\u2019s lymphoma. Lancet 1, 702\u2013703 (1964).","journal-title":"Lancet"},{"key":"775_CR23","unstructured":"Hjalgrim, H., Friborg, J. & Melbye, M. in Human Herpesviruses: Biology, Therapy, and Immunoprophylaxis (eds Arvin, A. et al.) (2007)."},{"key":"775_CR24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","volume":"343","author":"JI Cohen","year":"2000","unstructured":"Cohen, J. I. Epstein\u2013Barr virus infection. N. Engl. J. Med. 343, 481\u2013492 (2000).","journal-title":"N. Engl. J. Med."},{"key":"775_CR25","doi-asserted-by":"crossref","first-page":"3652","DOI":"10.1016\/j.cell.2022.08.026","volume":"185","author":"B Damania","year":"2022","unstructured":"Damania, B., Kenney, S. C. & Raab-Traub, N. Epstein\u2013Barr virus: biology and clinical disease. Cell 185, 3652\u20133670 (2022).","journal-title":"Cell"},{"key":"775_CR26","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jis646","volume":"207","author":"HH Balfour Jr.","year":"2013","unstructured":"Balfour, H. H. Jr. et al. Behavioral, virologic, and immunologic factors associated with acquisition and severity of primary Epstein\u2013Barr virus infection in university students. J. Infect. Dis. 207, 80\u201388 (2013).","journal-title":"J. Infect. Dis."},{"key":"775_CR27","doi-asserted-by":"crossref","first-page":"587380","DOI":"10.3389\/fimmu.2020.587380","volume":"11","author":"G Houen","year":"2020","unstructured":"Houen, G. & Trier, N. H. Epstein\u2013Barr virus and systemic autoimmune diseases. Front. Immunol. 11, 587380 (2020).","journal-title":"Front. Immunol."},{"key":"775_CR28","doi-asserted-by":"crossref","first-page":"010405","DOI":"10.7189\/jogh.10.010405","volume":"10","author":"D Bakkalci","year":"2020","unstructured":"Bakkalci, D. et al. Risk factors for Epstein\u2013Barr virus-associated cancers: a systematic review, critical appraisal, and mapping of the epidemiological evidence. J. Glob. Health 10, 010405 (2020).","journal-title":"J. Glob. Health"},{"key":"775_CR29","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/0306-9877(88)90024-2","volume":"25","author":"HB Warner","year":"1988","unstructured":"Warner, H. B. & Carp, R. I. Multiple sclerosis etiology \u2014 an Epstein\u2013Barr virus hypothesis. Med. Hypotheses 25, 93\u201397 (1988).","journal-title":"Med. Hypotheses"},{"key":"775_CR30","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/00001648-200105000-00009","volume":"12","author":"MA Hernan","year":"2001","unstructured":"Hernan, M. A., Zhang, S. M., Lipworth, L., Olek, M. J. & Ascherio, A. Multiple sclerosis and age at infection with common viruses. Epidemiology 12, 301\u2013306 (2001).","journal-title":"Epidemiology"},{"key":"775_CR31","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.1093\/brain\/awab100","volume":"144","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Hospital-diagnosed infections before age 20 and risk of a subsequent multiple sclerosis diagnosis. Brain 144, 2390\u20132400 (2021).","journal-title":"Brain"},{"key":"775_CR32","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jech.52.2.101","volume":"52","author":"NS Crowcroft","year":"1998","unstructured":"Crowcroft, N. S., Vyse, A., Brown, D. W. & Strachan, D. P. Epidemiology of Epstein\u2013Barr virus infection in pre-adolescent children: application of a new salivary method in Edinburgh, Scotland. J. Epidemiol. Community Health 52, 101\u2013104 (1998).","journal-title":"J. Epidemiol. Community Health"},{"key":"775_CR33","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMra020100","volume":"347","author":"JF Bach","year":"2002","unstructured":"Bach, J. F. The effect of infections on susceptibility to autoimmune and allergic diseases. N. Engl. J. Med. 347, 911\u2013920 (2002).","journal-title":"N. Engl. J. Med."},{"key":"775_CR34","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1002\/ana.21117","volume":"61","author":"A Ascherio","year":"2007","unstructured":"Ascherio, A. & Munger, K. L. Environmental risk factors for multiple sclerosis. Part I: the role of infection. Ann. Neurol. 61, 288\u2013299 (2007).","journal-title":"Ann. Neurol."},{"key":"775_CR35","volume":"4","author":"Y Xu","year":"2021","unstructured":"Xu, Y. et al. Association of infectious mononucleosis in childhood and adolescence with risk for a subsequent multiple sclerosis diagnosis among siblings. JAMA Netw. Open. 4, e2124932 (2021).","journal-title":"JAMA Netw. Open."},{"key":"775_CR36","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat. Rev. Neurol. 14, 577\u2013589 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"775_CR37","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","volume":"77","author":"K Bjornevik","year":"2020","unstructured":"Bjornevik, K. et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 77, 58\u201364 (2020).","journal-title":"JAMA Neurol."},{"key":"775_CR38","doi-asserted-by":"publisher","DOI":"10.1002\/acn3.51568","author":"D Jons","year":"2022","unstructured":"Jons, D. et al. Axonal injury in asymptomatic individuals preceding onset of multiple sclerosis. Ann. Clin. Transl. Neurol. https:\/\/doi.org\/10.1002\/acn3.51568 (2022).","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"775_CR39","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1017\/S0950268808000551","volume":"137","author":"JB Dowd","year":"2009","unstructured":"Dowd, J. B., Aiello, A. E. & Alley, D. E. Socioeconomic disparities in the seroprevalence of cytomegalovirus infection in the US population: NHANES III. Epidemiol. Infect. 137, 58\u201365 (2009).","journal-title":"Epidemiol. Infect."},{"key":"775_CR40","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jiac.2019.01.012","volume":"25","author":"T Ishii","year":"2019","unstructured":"Ishii, T. et al. Clinical differentiation of infectious mononucleosis that is caused by Epstein\u2013Barr virus or cytomegalovirus: a single-center case-control study in Japan. J. Infect. Chemother. 25, 431\u2013436 (2019).","journal-title":"J. Infect. Chemother."},{"key":"775_CR41","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/EDE.0b013e3181d61eeb","volume":"21","author":"M Lipsitch","year":"2010","unstructured":"Lipsitch, M., Tchetgen Tchetgen, E. & Cohen, T. Negative controls: a tool for detecting confounding and bias in observational studies. Epidemiology 21, 383\u2013388 (2010).","journal-title":"Epidemiology"},{"key":"775_CR42","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1111\/ene.14961","volume":"28","author":"V Grut","year":"2021","unstructured":"Grut, V. et al. Cytomegalovirus seropositivity is associated with reduced risk of multiple sclerosis-a presymptomatic case-control study. Eur. J. Neurol. 28, 3072\u20133079 (2021).","journal-title":"Eur. J. Neurol."},{"key":"775_CR43","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele, T. J. & Ding, P. Sensitivity analysis in observational research: introducing the e-value. Ann. Intern. Med. 167, 268\u2013274 (2017).","journal-title":"Ann. Intern. Med."},{"key":"775_CR44","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.virol.2005.09.015","volume":"344","author":"VR Racaniello","year":"2006","unstructured":"Racaniello, V. R. One hundred years of poliovirus pathogenesis. Virology 344, 9\u201316 (2006).","journal-title":"Virology"},{"key":"775_CR45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.tim.2010.10.002","volume":"19","author":"J Bodily","year":"2011","unstructured":"Bodily, J. & Laimins, L. A. Persistence of human papillomavirus infection: keys to malignant progression. Trends Microbiol. 19, 33\u201339 (2011).","journal-title":"Trends Microbiol."},{"key":"775_CR46","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1212\/WNL.0000000000001420","volume":"84","author":"R Mechelli","year":"2015","unstructured":"Mechelli, R. et al. Epstein\u2013Barr virus genetic variants are associated with multiple sclerosis. Neurology 84, 1362\u20131368 (2015).","journal-title":"Neurology"},{"key":"775_CR47","doi-asserted-by":"crossref","first-page":"2832","DOI":"10.1001\/jama.296.23.2832","volume":"296","author":"KL Munger","year":"2006","unstructured":"Munger, K. L., Levin, L. I., Hollis, B. W., Howard, N. S. & Ascherio, A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832\u20132838 (2006).","journal-title":"JAMA"},{"key":"775_CR48","doi-asserted-by":"crossref","first-page":"2140","DOI":"10.1212\/WNL.0b013e3182752ea8","volume":"79","author":"J Salzer","year":"2012","unstructured":"Salzer, J. et al. Vitamin D as a protective factor in multiple sclerosis. Neurology 79, 2140\u20132145 (2012).","journal-title":"Neurology"},{"key":"775_CR49","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1093\/aje\/154.1.69","volume":"154","author":"MA Hernan","year":"2001","unstructured":"Hernan, M. A., Olek, M. J. & Ascherio, A. Cigarette smoking and incidence of multiple sclerosis. Am. J. Epidemiol. 154, 69\u201374 (2001).","journal-title":"Am. J. Epidemiol."},{"key":"775_CR50","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/1352458512470862","volume":"19","author":"J Salzer","year":"2013","unstructured":"Salzer, J. et al. Smoking as a risk factor for multiple sclerosis. Mult. Scler. 19, 1022\u20131027 (2013).","journal-title":"Mult. Scler."},{"key":"775_CR51","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1177\/1352458513483889","volume":"19","author":"KL Munger","year":"2013","unstructured":"Munger, K. L. et al. Childhood body mass index and multiple sclerosis risk: a long-term cohort study. Mult. Scler. 19, 1323\u20131329 (2013).","journal-title":"Mult. Scler."},{"key":"775_CR52","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1212\/WNL.0b013e3181c0d6e0","volume":"73","author":"KL Munger","year":"2009","unstructured":"Munger, K. L., Chitnis, T. & Ascherio, A. Body size and risk of MS in two cohorts of US women. Neurology 73, 1543\u20131550 (2009).","journal-title":"Neurology"},{"key":"775_CR53","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1093\/brain\/awz088","volume":"142","author":"N Munk Nielsen","year":"2019","unstructured":"Munk Nielsen, N. et al. Multiple sclerosis among first- and second-generation immigrants in Denmark: a population-based cohort study. Brain 142, 1587\u20131597 (2019).","journal-title":"Brain"},{"key":"775_CR54","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1212\/WNL.53.8.1711","volume":"53","author":"MA Hernan","year":"1999","unstructured":"Hernan, M. A., Olek, M. J. & Ascherio, A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 53, 1711\u20131718 (1999).","journal-title":"Neurology"},{"key":"775_CR55","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/ana.10788","volume":"55","author":"MT Wallin","year":"2004","unstructured":"Wallin, M. T., Page, W. F. & Kurtzke, J. F. Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55, 65\u201371 (2004).","journal-title":"Ann. Neurol."},{"key":"775_CR56","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1093\/brain\/aws099","volume":"135","author":"MT Wallin","year":"2012","unstructured":"Wallin, M. T. et al. The Gulf War era multiple sclerosis cohort: age and incidence rates by race, sex and service. Brain 135, 1778\u20131785 (2012).","journal-title":"Brain"},{"key":"775_CR57","doi-asserted-by":"crossref","first-page":"e1954","DOI":"10.1212\/WNL.0000000000005612","volume":"90","author":"N Koch-Henriksen","year":"2018","unstructured":"Koch-Henriksen, N., Thygesen, L. C., Stenager, E., Laursen, B. & Magyari, M. Incidence of MS has increased markedly over six decades in Denmark particularly with late onset and in women. Neurology 90, e1954\u2013e1963 (2018).","journal-title":"Neurology"},{"key":"775_CR58","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1038\/ng.3395","volume":"47","author":"L Moutsianas","year":"2015","unstructured":"Moutsianas, L. et al. Class II HLA interactions modulate genetic risk for multiple sclerosis. Nat. Genet. 47, 1107\u20131113 (2015).","journal-title":"Nat. Genet."},{"key":"775_CR59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0119605","volume":"10","author":"VA Ricigliano","year":"2015","unstructured":"Ricigliano, V. A. et al. EBNA2 binds to genomic intervals associated with multiple sclerosis and overlaps with vitamin D receptor occupancy. PLoS One 10, e0119605 (2015).","journal-title":"PLoS One"},{"key":"775_CR60","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/s41588-018-0102-3","volume":"50","author":"JB Harley","year":"2018","unstructured":"Harley, J. B. et al. Transcription factors operate across disease loci, with EBNA2 implicated in autoimmunity. Nat. Genet. 50, 699\u2013707 (2018).","journal-title":"Nat. Genet."},{"key":"775_CR61","volume":"10","author":"A Afrasiabi","year":"2020","unstructured":"Afrasiabi, A., Parnell, G. P., Swaminathan, S., Stewart, G. J. & Booth, D. R. The interaction of multiple sclerosis risk loci with Epstein\u2013Barr virus phenotypes implicates the virus in pathogenesis. Sci. Rep. 10, 193 (2020).","journal-title":"Sci. Rep."},{"key":"775_CR62","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrneurol.2016.187","volume":"13","author":"T Olsson","year":"2017","unstructured":"Olsson, T., Barcellos, L. F. & Alfredsson, L. Interactions between genetic, lifestyle and environmental risk factors for multiple sclerosis. Nat. Rev. Neurol. 13, 25\u201336 (2017).","journal-title":"Nat. Rev. Neurol."},{"key":"775_CR63","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0036-1579693","volume":"36","author":"A Ascherio","year":"2016","unstructured":"Ascherio, A. & Munger, K. L. Epidemiology of multiple sclerosis: from risk factors to prevention \u2014 an update. Semin. Neurol. 36, 103\u2013114 (2016).","journal-title":"Semin. Neurol."},{"key":"775_CR64","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/0959-8049(93)90299-U","volume":"29A","author":"ET Lennette","year":"1993","unstructured":"Lennette, E. T. et al. Disease-related differences in antibody patterns against EBV-encoded nuclear antigens EBNA 1, EBNA 2 and EBNA 6. Eur. J. Cancer 29A, 1584\u20131589 (1993).","journal-title":"Eur. J. Cancer"},{"key":"775_CR65","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/ana.25532","volume":"86","author":"KL Munger","year":"2019","unstructured":"Munger, K. L. et al. Epstein\u2013Barr virus and multiple sclerosis risk in the finnish maternity cohort. Ann. Neurol. 86, 436\u2013442 (2019).","journal-title":"Ann. Neurol."},{"key":"775_CR66","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.3389\/fneur.2019.01368","volume":"10","author":"AK Hedstrom","year":"2019","unstructured":"Hedstrom, A. K. et al. High levels of Epstein\u2013Barr virus nuclear antigen-1-specific antibodies and infectious mononucleosis act both independently and synergistically to increase multiple sclerosis risk. Front. Neurol. 10, 1368 (2019).","journal-title":"Front. Neurol."},{"key":"775_CR67","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/s41582-021-00519-3","volume":"17","author":"N Makhani","year":"2021","unstructured":"Makhani, N. & Tremlett, H. The multiple sclerosis prodrome. Nat. Rev. Neurol. 17, 515\u2013521 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"775_CR68","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/nrc797","volume":"2","author":"C Boshoff","year":"2002","unstructured":"Boshoff, C. & Weiss, R. AIDS-related malignancies. Nat. Rev. Cancer 2, 373\u2013382 (2002).","journal-title":"Nat. Rev. Cancer"},{"key":"775_CR69","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1136\/jnnp-2014-307932","volume":"86","author":"J Gold","year":"2015","unstructured":"Gold, J. et al. HIV and lower risk of multiple sclerosis: beginning to unravel a mystery using a record-linked database study. J. Neurol. Neurosurg. Psychiatry 86, 9\u201312 (2015).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"775_CR70","doi-asserted-by":"crossref","first-page":"12368","DOI":"10.1073\/pnas.2002392117","volume":"117","author":"NC Drosu","year":"2020","unstructured":"Drosu, N. C., Edelman, E. R. & Housman, D. E. Tenofovir prodrugs potently inhibit Epstein\u2013Barr virus lytic DNA replication by targeting the viral DNA polymerase. Proc. Natl Acad. Sci. USA 117, 12368\u201312374 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR71","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1146\/annurev-immunol-032414-112326","volume":"33","author":"GS Taylor","year":"2015","unstructured":"Taylor, G. S., Long, H. M., Brooks, J. M., Rickinson, A. B. & Hislop, A. D. The immunology of Epstein\u2013Barr virus-induced disease. Annu. Rev. Immunol. 33, 787\u2013821 (2015).","journal-title":"Annu. Rev. Immunol."},{"key":"775_CR72","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1038\/s41579-019-0249-7","volume":"17","author":"C M\u00fcnz","year":"2019","unstructured":"M\u00fcnz, C. Latency and lytic replication in the oncogenesis of the Epstein\u2013Barr virus. Nat. Rev. Microbiol. 17, 691\u2013700 (2019).","journal-title":"Nat. Rev. Microbiol."},{"key":"775_CR73","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1146\/annurev-pathmechdis-012418-013023","volume":"14","author":"PJ Farrell","year":"2019","unstructured":"Farrell, P. J. Epstein\u2013Barr virus and cancer. Annu. Rev. Pathol. 14, 29\u201353 (2019).","journal-title":"Annu. Rev. Pathol."},{"key":"775_CR74","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jcv.2018.03.001","volume":"102","author":"SK Dunmire","year":"2018","unstructured":"Dunmire, S. K., Verghese, P. S. & Balfour, H. H. Jr. Primary Epstein\u2013Barr virus infection. J. Clin. Virol. 102, 84\u201392 (2018).","journal-title":"J. Clin. Virol."},{"key":"775_CR75","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1093\/femsre\/fuy044","volume":"43","author":"B Damania","year":"2019","unstructured":"Damania, B. & M\u00fcnz, C. Immunodeficiencies that predispose to pathologies by human oncogenic gamma-herpesviruses. FEMS Microbiol. Rev. 43, 181\u2013192 (2019).","journal-title":"FEMS Microbiol. Rev."},{"key":"775_CR76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.coi.2021.04.003","volume":"72","author":"B Fournier","year":"2021","unstructured":"Fournier, B. & Latour, S. Immunity to EBV as revealed by immunedeficiencies. Curr. Opin. Immunol. 72, 107\u2013115 (2021).","journal-title":"Curr. Opin. Immunol."},{"key":"775_CR77","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1111\/imr.12791","volume":"291","author":"S Latour","year":"2019","unstructured":"Latour, S. & Fischer, A. Signaling pathways involved in the T-cell-mediated immunity against Epstein\u2013Barr virus: lessons from genetic diseases. Immunol. Rev. 291, 174\u2013189 (2019).","journal-title":"Immunol. Rev."},{"key":"775_CR78","doi-asserted-by":"crossref","first-page":"20180296","DOI":"10.1098\/rstb.2018.0296","volume":"374","author":"D McHugh","year":"2019","unstructured":"McHugh, D. et al. Infection and immune control of human oncogenic gamma-herpesviruses in humanized mice. Philos. Trans. R. Soc. Lond. B Biol. Sci. 374, 20180296 (2019).","journal-title":"Philos. Trans. R. Soc. Lond. B Biol. Sci."},{"key":"775_CR79","doi-asserted-by":"crossref","first-page":"100352","DOI":"10.1016\/j.xcrm.2021.100352","volume":"2","author":"J Muhe","year":"2021","unstructured":"Muhe, J. et al. Neutralizing antibodies against Epstein\u2013Barr virus infection of B cells can protect from oral viral challenge in the rhesus macaque animal model. Cell Rep. Med. 2, 100352 (2021).","journal-title":"Cell Rep. Med."},{"key":"775_CR80","first-page":"385","volume":"391","author":"J Muhe","year":"2015","unstructured":"Muhe, J. & Wang, F. Non-human primate lymphocryptoviruses: past, present, and future. Curr. Top. Microbiol. Immunol. 391, 385\u2013405 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"775_CR81","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1182\/bloodadvances.2018025536","volume":"3","author":"C Gujer","year":"2019","unstructured":"Gujer, C. et al. Plasmacytoid dendritic cells respond to Epstein\u2013Barr virus infection with a distinct type I interferon subtype profile. Blood Adv. 3, 1129\u20131144 (2019).","journal-title":"Blood Adv."},{"key":"775_CR82","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/j.celrep.2013.11.041","volume":"5","author":"O Chijioke","year":"2013","unstructured":"Chijioke, O. et al. Human natural killer cells prevent infectious mononucleosis features by targeting lytic Epstein\u2013Barr virus infection. Cell Rep. 5, 1489\u20131498 (2013).","journal-title":"Cell Rep."},{"key":"775_CR83","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.ccr.2014.07.026","volume":"26","author":"Z Xiang","year":"2014","unstructured":"Xiang, Z. et al. Targeted activation of human V\u03b39V\u03b42-T cells controls Epstein\u2013Barr virus-induced B cell lymphoproliferative disease. Cancer Cell 26, 565\u2013576 (2014).","journal-title":"Cancer Cell"},{"key":"775_CR84","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1182\/blood-2013-01-480665","volume":"122","author":"BK Chung","year":"2013","unstructured":"Chung, B. K. et al. Innate immune control of EBV-infected B cells by invariant natural killer T cells. Blood 122, 2600\u20132608 (2013).","journal-title":"Blood"},{"key":"775_CR85","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1084\/jem.20081720","volume":"206","author":"T Strowig","year":"2009","unstructured":"Strowig, T. et al. Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J. Exp. Med. 206, 1423\u20131434 (2009).","journal-title":"J. Exp. Med."},{"key":"775_CR86","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1084\/jem.187.9.1395","volume":"187","author":"MF Callan","year":"1998","unstructured":"Callan, M. F. et al. Direct visualization of antigen-specific CD8+ T cells during the primary immune response to Epstein\u2013Barr virus In vivo. J. Exp. Med. 187, 1395\u20131402 (1998).","journal-title":"J. Exp. Med."},{"key":"775_CR87","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.blre.2017.11.004","volume":"32","author":"ML Grant","year":"2018","unstructured":"Grant, M. L. & Bollard, C. M. Cell therapies for hematological malignancies: don\u2019t forget non-gene-modified t cells! Blood Rev. 32, 203\u2013224 (2018).","journal-title":"Blood Rev."},{"key":"775_CR88","first-page":"289","volume":"391","author":"JM Middeldorp","year":"2015","unstructured":"Middeldorp, J. M. Epstein\u2013Barr virus-specific humoral immune responses in health and disease. Curr. Top. Microbiol. Immunol. 391, 289\u2013323 (2015).","journal-title":"Curr. Top. Microbiol. Immunol."},{"key":"775_CR89","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/s41586-022-04432-7","volume":"603","author":"TV Lanz","year":"2022","unstructured":"Lanz, T. V. et al. Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM. Nature 603, 321\u2013327 (2022).","journal-title":"Nature"},{"key":"775_CR90","doi-asserted-by":"crossref","first-page":"16955","DOI":"10.1073\/pnas.1902623116","volume":"116","author":"K Tengvall","year":"2019","unstructured":"Tengvall, K. et al. Molecular mimicry between Anoctamin 2 and Epstein\u2013Barr virus nuclear antigen 1 associates with multiple sclerosis risk. Proc. Natl Acad. Sci. USA 116, 16955\u201316960 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR91","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jneuroim.2009.08.004","volume":"215","author":"P Sundstrom","year":"2009","unstructured":"Sundstrom, P., Nystrom, M., Ruuth, K. & Lundgren, E. Antibodies to specific EBNA-1 domains and HLA DRB1*1501 interact as risk factors for multiple sclerosis. J. Neuroimmunol. 215, 102\u2013107 (2009).","journal-title":"J. Neuroimmunol."},{"key":"775_CR92","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jneuroim.2017.07.013","volume":"310","author":"JW Lindsey","year":"2017","unstructured":"Lindsey, J. W. Antibodies to the Epstein\u2013Barr virus proteins BFRF3 and BRRF2 cross-react with human proteins. J. Neuroimmunol. 310, 131\u2013134 (2017).","journal-title":"J. Neuroimmunol."},{"key":"775_CR93","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1172\/JCI200523661","volume":"115","author":"S Cepok","year":"2005","unstructured":"Cepok, S. et al. Identification of Epstein\u2013Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 115, 1352\u20131360 (2005).","journal-title":"J. Clin. Invest."},{"key":"775_CR94","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11481-020-09948-1","volume":"16","author":"Z Wang","year":"2021","unstructured":"Wang, Z. et al. Antibodies from multiple sclerosis brain identified Epstein\u2013Barr virus nuclear antigen 1 & 2 epitopes which are recognized by oligoclonal bands. J. Neuroimmune Pharmacol. 16, 567\u2013580 (2021).","journal-title":"J. Neuroimmune Pharmacol."},{"key":"775_CR95","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1212\/WNL.42.9.1798","volume":"42","author":"PF Bray","year":"1992","unstructured":"Bray, P. F., Luka, J., Bray, P. F., Culp, K. W. & Schlight, J. P. Antibodies against Epstein\u2013Barr nuclear antigen (EBNA) in multiple sclerosis CSF, and two pentapeptide sequence identities between EBNA and myelin basic protein. Neurology 42, 1798\u20131804 (1992).","journal-title":"Neurology"},{"key":"775_CR96","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.jneuroim.2010.04.007","volume":"225","author":"V Nociti","year":"2010","unstructured":"Nociti, V. et al. Epstein\u2013Barr virus antibodies in serum and cerebrospinal fluid from multiple sclerosis, chronic inflammatory demyelinating polyradiculoneuropathy and amyotrophic lateral sclerosis. J. Neuroimmunol. 225, 149\u2013152 (2010).","journal-title":"J. Neuroimmunol."},{"key":"775_CR97","doi-asserted-by":"crossref","first-page":"577868","DOI":"10.1016\/j.jneuroim.2022.577868","volume":"367","author":"C Kyllesbech","year":"2022","unstructured":"Kyllesbech, C. et al. Virus-specific antibody indices may supplement the total IgG index in diagnostics of multiple sclerosis. J. Neuroimmunol. 367, 577868 (2022).","journal-title":"J. Neuroimmunol."},{"key":"775_CR98","doi-asserted-by":"crossref","first-page":"102332","DOI":"10.1016\/j.jaut.2019.102332","volume":"106","author":"NR Jog","year":"2020","unstructured":"Jog, N. R. et al. Epstein\u2013Barr virus nuclear antigen 1 (EBNA-1) peptides recognized by adult multiple sclerosis patient sera induce neurologic symptoms in a murine model. J. Autoimmun. 106, 102332 (2020).","journal-title":"J. Autoimmun."},{"key":"775_CR99","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1084\/jem.20160120","volume":"213","author":"JS Kalchschmidt","year":"2016","unstructured":"Kalchschmidt, J. S. et al. Epstein\u2013Barr virus nuclear protein EBNA3C directly induces expression of AID and somatic mutations in B cells. J. Exp. Med. 213, 921\u2013928 (2016).","journal-title":"J. Exp. Med."},{"key":"775_CR100","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.4049\/jimmunol.171.10.5215","volume":"171","author":"B He","year":"2003","unstructured":"He, B., Raab-Traub, N., Casali, P. & Cerutti, A. EBV-encoded latent membrane protein 1 cooperates with BAFF\/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J. Immunol. 171, 5215\u20135224 (2003).","journal-title":"J. Immunol."},{"key":"775_CR101","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/35095584","volume":"1","author":"DA Thorley-Lawson","year":"2001","unstructured":"Thorley-Lawson, D. A. Epstein\u2013Barr virus: exploiting the immune system. Nat. Rev. Immunol. 1, 75\u201382 (2001).","journal-title":"Nat. Rev. Immunol."},{"key":"775_CR102","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","volume":"17","author":"MT Cencioni","year":"2021","unstructured":"Cencioni, M. T., Mattoscio, M., Magliozzi, R., Bar-Or, A. & Muraro, P. A. B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies. Nat. Rev. Neurol. 17, 399\u2013414 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"775_CR103","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jneuroim.2014.08.617","volume":"276","author":"V Studer","year":"2014","unstructured":"Studer, V., Rossi, S., Motta, C., Buttari, F. & Centonze, D. Peripheral B cell depletion and central proinflammatory cytokine reduction following repeated intrathecal administration of rituximab in progressive Multiple Sclerosis. J. Neuroimmunol. 276, 229\u2013231 (2014).","journal-title":"J. Neuroimmunol."},{"key":"775_CR104","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003220","volume":"9","author":"DF Angelini","year":"2013","unstructured":"Angelini, D. F. et al. Increased CD8+ T cell response to Epstein\u2013Barr virus lytic antigens in the active phase of multiple sclerosis. PLoS Pathog. 9, e1003220 (2013).","journal-title":"PLoS Pathog."},{"key":"775_CR105","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1046\/j.1365-2249.2003.02114.x","volume":"132","author":"P Hollsberg","year":"2003","unstructured":"Hollsberg, P., Hansen, H. J. & Haahr, S. Altered CD8+ T cell responses to selected Epstein\u2013Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin. Exp. Immunol. 132, 137\u2013143 (2003).","journal-title":"Clin. Exp. Immunol."},{"key":"775_CR106","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/brain\/awn108","volume":"131","author":"S Jilek","year":"2008","unstructured":"Jilek, S. et al. Strong EBV-specific CD8+ T-cell response in patients with early multiple sclerosis. Brain 131, 1712\u20131721 (2008).","journal-title":"Brain"},{"key":"775_CR107","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1093\/brain\/awl067","volume":"129","author":"JD Lunemann","year":"2006","unstructured":"Lunemann, J. D. et al. Increased frequency and broadened specificity of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129, 1493\u20131506 (2006).","journal-title":"Brain"},{"key":"775_CR108","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1084\/jem.20072397","volume":"205","author":"JD Lunemann","year":"2008","unstructured":"Lunemann, J. D. et al. EBNA1-specific T cells from patients with multiple sclerosis cross react with myelin antigens and co-produce IFN-\u03b3 and IL-2. J. Exp. Med. 205, 1763\u20131773 (2008).","journal-title":"J. Exp. Med."},{"key":"775_CR109","volume":"219","author":"T Schneider-Hohendorf","year":"2022","unstructured":"Schneider-Hohendorf, T. et al. Broader Epstein\u2013Barr virus-specific T cell receptor repertoire in patients with multiple sclerosis. J. Exp. Med. 219, e20220650 (2022).","journal-title":"J. Exp. Med."},{"key":"775_CR110","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1002\/eji.201444662","volume":"44","author":"A Lossius","year":"2014","unstructured":"Lossius, A. et al. High-throughput sequencing of TCR repertoires in multiple sclerosis reveals intrathecal enrichment of EBV-reactive CD8+ T cells. Eur. J. Immunol. 44, 3439\u20133452 (2014).","journal-title":"Eur. J. Immunol."},{"key":"775_CR111","doi-asserted-by":"crossref","DOI":"10.1038\/cti.2017.25","volume":"6","author":"MP Pender","year":"2017","unstructured":"Pender, M. P., Csurhes, P. A., Burrows, J. M. & Burrows, S. R. Defective T-cell control of Epstein\u2013Barr virus infection in multiple sclerosis. Clin. Transl. Immunol. 6, e126 (2017).","journal-title":"Clin. Transl. Immunol."},{"key":"775_CR112","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jneuroim.2016.03.010","volume":"294","author":"H Erdur","year":"2016","unstructured":"Erdur, H. et al. EBNA1 antigen-specific CD8+ T cells in cerebrospinal fluid of patients with multiple sclerosis. J. Neuroimmunol. 294, 14\u201317 (2016).","journal-title":"J. Neuroimmunol."},{"key":"775_CR113","doi-asserted-by":"crossref","first-page":"4671","DOI":"10.4049\/jimmunol.1103100","volume":"188","author":"S Jilek","year":"2012","unstructured":"Jilek, S. et al. HLA-B7-restricted EBV-specific CD8+ T cells are dysregulated in multiple sclerosis. J. Immunol. 188, 4671\u20134680 (2012).","journal-title":"J. Immunol."},{"key":"775_CR114","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/eji.202048655","volume":"51","author":"H Zdimerova","year":"2021","unstructured":"Zdimerova, H. et al. Attenuated immune control of Epstein\u2013Barr virus in humanized mice is associated with the multiple sclerosis risk factor HLA-DR15. Eur. J. Immunol. 51, 64\u201375 (2021).","journal-title":"Eur. J. Immunol."},{"key":"775_CR115","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.cell.2020.09.054","volume":"183","author":"J Wang","year":"2020","unstructured":"Wang, J. et al. HLA-DR15 molecules jointly shape an autoreactive T cell repertoire in multiple sclerosis. Cell 183, 1264\u20131281.e20 (2020).","journal-title":"Cell"},{"key":"775_CR116","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/0092-8674(95)90348-8","volume":"80","author":"KW Wucherpfennig","year":"1995","unstructured":"Wucherpfennig, K. W. & Strominger, J. L. Molecular mimicry in T cell-mediated autoimmunity: viral peptides activate human T cell clones specific for myelin basic protein. Cell 80, 695\u2013705 (1995).","journal-title":"Cell"},{"key":"775_CR117","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1038\/ni835","volume":"3","author":"HL Lang","year":"2002","unstructured":"Lang, H. L. et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3, 940\u2013943 (2002).","journal-title":"Nat. Immunol."},{"key":"775_CR118","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1182\/blood-2012-08-450775","volume":"121","author":"CS Leung","year":"2013","unstructured":"Leung, C. S. et al. Robust T-cell stimulation by Epstein\u2013Barr virus-transformed B cells after antigen targeting to DEC-205. Blood 121, 1584\u20131594 (2013).","journal-title":"Blood"},{"key":"775_CR119","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.immuni.2018.08.012","volume":"49","author":"S Hong","year":"2018","unstructured":"Hong, S. et al. B cells are the dominant antigen-presenting cells that activate naive CD4+ T cells upon immunization with a virus-derived nanoparticle antigen. Immunity 49, 695\u2013708.e4 (2018).","journal-title":"Immunity"},{"key":"775_CR120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1007464","volume":"14","author":"DG van Zyl","year":"2018","unstructured":"van Zyl, D. G. et al. Immunogenic particles with a broad antigenic spectrum stimulate cytolytic T cells and offer increased protection against EBV infection ex vivo and in mice. PLoS Pathog. 14, e1007464 (2018).","journal-title":"PLoS Pathog."},{"key":"775_CR121","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/s41586-020-03075-w","volume":"590","author":"IK Choi","year":"2021","unstructured":"Choi, I. K. et al. Mechanism of EBV inducing anti-tumour immunity and its therapeutic use. Nature 590, 157\u2013162 (2021).","journal-title":"Nature"},{"key":"775_CR122","first-page":"E686","volume":"115","author":"IK Choi","year":"2018","unstructured":"Choi, I. K. et al. Signaling by the Epstein\u2013Barr virus LMP1 protein induces potent cytotoxic CD4+ and CD8+ T cell responses. Proc. Natl Acad. Sci. USA 115, E686\u2013E695 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR123","doi-asserted-by":"crossref","first-page":"103572","DOI":"10.1016\/j.ebiom.2021.103572","volume":"71","author":"JT Keane","year":"2021","unstructured":"Keane, J. T. et al. The interaction of Epstein\u2013Barr virus encoded transcription factor EBNA2 with multiple sclerosis risk loci is dependent on the risk genotype. EBioMedicine 71, 103572 (2021).","journal-title":"EBioMedicine"},{"key":"775_CR124","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41590-019-0427-9","volume":"20","author":"K Kwak","year":"2019","unstructured":"Kwak, K., Akkaya, M. & Pierce, S. K. B cell signaling in context. Nat. Immunol. 20, 963\u2013969 (2019).","journal-title":"Nat. Immunol."},{"key":"775_CR125","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1001\/jama.286.24.3083","volume":"286","author":"A Ascherio","year":"2001","unstructured":"Ascherio, A. et al. Epstein\u2013Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083\u20133088 (2001).","journal-title":"JAMA"},{"key":"775_CR126","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1002\/ana.21886","volume":"67","author":"JD Lunemann","year":"2010","unstructured":"Lunemann, J. D. et al. Elevated Epstein\u2013Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis. Ann. Neurol. 67, 159\u2013169 (2010).","journal-title":"Ann. Neurol."},{"key":"775_CR127","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1212\/WNL.0000000000002099","volume":"85","author":"KL Munger","year":"2015","unstructured":"Munger, K. L. et al. No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. Neurology 85, 1694\u20131701 (2015).","journal-title":"Neurology"},{"key":"775_CR128","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1212\/WNL.0b013e3181aa29fe","volume":"73","author":"RA Farrell","year":"2009","unstructured":"Farrell, R. A. et al. Humoral immune response to EBV in multiple sclerosis is associated with disease activity on MRI. Neurology 73, 32\u201338 (2009).","journal-title":"Neurology"},{"key":"775_CR129","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1177\/1352458514533843","volume":"20","author":"S Kvistad","year":"2014","unstructured":"Kvistad, S. et al. Antibodies to Epstein\u2013Barr virus and MRI disease activity in multiple sclerosis. Mult. Scler. 20, 1833\u20131840 (2014).","journal-title":"Mult. Scler."},{"key":"775_CR130","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1177\/1352458508092353","volume":"14","author":"P Sundstrom","year":"2008","unstructured":"Sundstrom, P., Nystrom, L., Jidell, E. & Hallmans, G. EBNA-1 reactivity and HLA DRB1*1501 as statistically independent risk factors for multiple sclerosis: a case-control study. Mult. Scler. 14, 1120\u20131122 (2008).","journal-title":"Mult. Scler."},{"key":"775_CR131","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1212\/WNL.0b013e31821e552a","volume":"76","author":"E Waubant","year":"2011","unstructured":"Waubant, E. et al. Common viruses associated with lower pediatric multiple sclerosis risk. Neurology 76, 1989\u20131995 (2011).","journal-title":"Neurology"},{"key":"775_CR132","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1111\/j.1750-3639.2004.tb00049.x","volume":"14","author":"B Serafini","year":"2004","unstructured":"Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E. & Aloisi, F. Detection of ectopic B-cell follicles with germinal centers in the meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 14, 164\u2013174 (2004).","journal-title":"Brain Pathol."},{"key":"775_CR133","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1093\/brain\/awm038","volume":"130","author":"R Magliozzi","year":"2007","unstructured":"Magliozzi, R. et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain 130, 1089\u20131104 (2007).","journal-title":"Brain"},{"key":"775_CR134","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-14118-w","volume":"11","author":"D Schafflick","year":"2020","unstructured":"Schafflick, D. et al. Integrated single cell analysis of blood and cerebrospinal fluid leukocytes in multiple sclerosis. Nat. Commun. 11, 247 (2020).","journal-title":"Nat. Commun."},{"key":"775_CR135","doi-asserted-by":"crossref","first-page":"22932","DOI":"10.1073\/pnas.2008523117","volume":"117","author":"A Ramesh","year":"2020","unstructured":"Ramesh, A. et al. A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis. Proc. Natl Acad. Sci. USA 117, 22932\u201322943 (2020).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR136","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1177\/13524585211032510","volume":"28","author":"M Pitteri","year":"2022","unstructured":"Pitteri, M. et al. Cerebrospinal fluid inflammatory profile of cognitive impairment in newly diagnosed multiple sclerosis patients. Mult. Scler. 28, 768\u2013777 (2022).","journal-title":"Mult. Scler."},{"key":"775_CR137","doi-asserted-by":"crossref","first-page":"102467","DOI":"10.1016\/j.msard.2020.102467","volume":"46","author":"H Nohejlova","year":"2020","unstructured":"Nohejlova, H. et al. Paediatric onset of multiple sclerosis: Analysis of chemokine and cytokine levels in the context of the early clinical course. Mult. Scler. Relat. Disord. 46, 102467 (2020).","journal-title":"Mult. Scler. Relat. Disord."},{"key":"775_CR138","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1002\/ana.25508","volume":"86","author":"J van Langelaar","year":"2019","unstructured":"van Langelaar, J. et al. Induction of brain-infiltrating T-bet-expressing B cells in multiple sclerosis. Ann. Neurol. 86, 264\u2013278 (2019).","journal-title":"Ann. Neurol."},{"key":"775_CR139","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1172\/JCI58092","volume":"122","author":"RE White","year":"2012","unstructured":"White, R. E. et al. EBNA3B-deficient EBV promotes B cell lymphomagenesis in humanized mice and is found in human tumors. J. Clin. Invest. 122, 1487\u20131502 (2012).","journal-title":"J. Clin. Invest."},{"key":"775_CR140","doi-asserted-by":"crossref","first-page":"10719","DOI":"10.1073\/pnas.1711233114","volume":"114","author":"K Berer","year":"2017","unstructured":"Berer, K. et al. Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc. Natl Acad. Sci. USA 114, 10719\u201310724 (2017).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR141","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1038\/nature10554","volume":"479","author":"K Berer","year":"2011","unstructured":"Berer, K. et al. Commensal microbiota and myelin autoantigen cooperate to trigger autoimmune demyelination. Nature 479, 538\u2013541 (2011).","journal-title":"Nature"},{"key":"775_CR142","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/j.coi.2013.09.009","volume":"25","author":"H Wekerle","year":"2013","unstructured":"Wekerle, H., Berer, K. & Krishnamoorthy, G. Remote control-triggering of brain autoimmune disease in the gut. Curr. Opin. Immunol. 25, 683\u2013689 (2013).","journal-title":"Curr. Opin. Immunol."},{"key":"775_CR143","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.celrep.2019.09.002","volume":"29","author":"D Duc","year":"2019","unstructured":"Duc, D. et al. Disrupting myelin-specific Th17 cell gut homing confers protection in an adoptive transfer experimental autoimmune encephalomyelitis. Cell Rep. 29, 378\u2013390.e4 (2019).","journal-title":"Cell Rep."},{"key":"775_CR144","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S1074-7613(02)00318-7","volume":"16","author":"LL Laichalk","year":"2002","unstructured":"Laichalk, L. L., Hochberg, D., Babcock, G. J., Freeman, R. B. & Thorley-Lawson, D. A. The dispersal of mucosal memory B cells: evidence from persistent EBV infection. Immunity 16, 745\u2013754 (2002).","journal-title":"Immunity"},{"key":"775_CR145","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.0040096","volume":"4","author":"O Gasser","year":"2007","unstructured":"Gasser, O. et al. HIV patients developing primary CNS lymphoma lack EBV-specific CD4+ T cell function irrespective of absolute CD4+ T cell counts. PLoS Med. 4, e96 (2007).","journal-title":"PLoS Med."},{"key":"775_CR146","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1182\/blood.2020009968","volume":"137","author":"M Roschewski","year":"2021","unstructured":"Roschewski, M. & Phelan, J. D. Sorting biologic subtypes of primary CNS lymphoma. Blood 137, 1436\u20131437 (2021).","journal-title":"Blood"},{"key":"775_CR147","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41591-019-0523-2","volume":"25","author":"DB Johnson","year":"2019","unstructured":"Johnson, D. B. et al. A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. Nat. Med. 25, 1243\u20131250 (2019).","journal-title":"Nat. Med."},{"key":"775_CR148","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1084\/jem.20071030","volume":"204","author":"B Serafini","year":"2007","unstructured":"Serafini, B. et al. Dysregulated Epstein\u2013Barr virus infection in the multiple sclerosis brain. J. Exp. Med. 204, 2899\u20132912 (2007).","journal-title":"J. Exp. Med."},{"key":"775_CR149","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-017-1049-5","volume":"15","author":"C Veroni","year":"2018","unstructured":"Veroni, C., Serafini, B., Rosicarelli, B., Fagnani, C. & Aloisi, F. Transcriptional profile and Epstein\u2013Barr virus infection status of laser-cut immune infiltrates from the brain of patients with progressive multiple sclerosis. J. Neuroinflammation 15, 18 (2018).","journal-title":"J. Neuroinflammation"},{"key":"775_CR150","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000466","volume":"5","author":"MA Moreno","year":"2018","unstructured":"Moreno, M. A. et al. Molecular signature of Epstein\u2013Barr virus infection in MS brain lesions. Neurol. Neuroimmunol. Neuroinflamm. 5, e466 (2018).","journal-title":"Neurol. Neuroimmunol. Neuroinflamm."},{"key":"775_CR151","doi-asserted-by":"crossref","DOI":"10.1093\/brain\/awp296","volume":"133","author":"LA Peferoen","year":"2010","unstructured":"Peferoen, L. A. et al. Epstein\u2013Barr virus is not a characteristic feature in the central nervous system in established multiple sclerosis. Brain 133, e137 (2010).","journal-title":"Brain"},{"key":"775_CR152","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1093\/brain\/awp200","volume":"132","author":"SN Willis","year":"2009","unstructured":"Willis, S. N. et al. Epstein\u2013Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain 132, 3318\u20133328 (2009).","journal-title":"Brain"},{"key":"775_CR153","doi-asserted-by":"crossref","first-page":"e00980-19","DOI":"10.1128\/JVI.00980-19","volume":"93","author":"B Serafini","year":"2019","unstructured":"Serafini, B., Rosicarelli, B., Veroni, C., Mazzola, G. A. & Aloisi, F. Epstein\u2013Barr virus-specific CD8 T cells selectively infiltrate the brain in multiple sclerosis and interact locally with virus-infected cells: clue for a virus-driven immunopathological mechanism. J. Virol. 93, e00980-19 (2019).","journal-title":"J. Virol."},{"key":"775_CR154","doi-asserted-by":"crossref","first-page":"16046","DOI":"10.1073\/pnas.1901314116","volume":"116","author":"P Mrozek-Gorska","year":"2019","unstructured":"Mrozek-Gorska, P. et al. Epstein\u2013Barr virus reprograms human B lymphocytes immediately in the prelatent phase of infection. Proc. Natl Acad. Sci. USA 116, 16046\u201316055 (2019).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"775_CR155","doi-asserted-by":"crossref","first-page":"1001145","DOI":"10.3389\/fimmu.2022.1001145","volume":"13","author":"ED SoRelle","year":"2022","unstructured":"SoRelle, E. D., Reinoso-Vizcaino, N. M., Horn, G. Q. & Luftig, M. A. Epstein\u2013Barr virus perpetuates B cell germinal center dynamics and generation of autoimmune-associated phenotypes in vitro. Front. Immunol. 13, 1001145 (2022).","journal-title":"Front. Immunol."},{"key":"775_CR156","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1002\/eji.202048739","volume":"51","author":"J van Langelaar","year":"2021","unstructured":"van Langelaar, J. et al. The association of Epstein\u2013Barr virus infection with CXCR3+ B-cell development in multiple sclerosis: impact of immunotherapies. Eur. J. Immunol. 51, 626\u2013633 (2021).","journal-title":"Eur. J. Immunol."},{"key":"775_CR157","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009618","volume":"17","author":"SS Soldan","year":"2021","unstructured":"Soldan, S. S. et al. Epigenetic plasticity enables CNS-trafficking of EBV-infected B lymphocytes. PLoS Pathog. 17, e1009618 (2021).","journal-title":"PLoS Pathog."},{"key":"775_CR158","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1038\/318287a0","volume":"318","author":"MA Epstein","year":"1985","unstructured":"Epstein, M. A., Morgan, A. J., Finerty, S., Randle, B. J. & Kirkwood, J. K. Protection of cottontop tamarins against Epstein\u2013Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature 318, 287\u2013289 (1985).","journal-title":"Nature"},{"key":"775_CR159","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.immuni.2019.03.010","volume":"50","author":"W Bu","year":"2019","unstructured":"Bu, W. et al. Immunization with components of the viral fusion apparatus elicits antibodies that neutralize Epstein\u2013Barr virus in B cells and epithelial cells. Immunity 50, 1305\u20131316.e6 (2019).","journal-title":"Immunity"},{"key":"775_CR160","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1086\/523813","volume":"196","author":"EM Sokal","year":"2007","unstructured":"Sokal, E. M. et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein\u2013Barr virus vaccine in healthy young adults. J. Infect. Dis. 196, 1749\u20131753 (2007).","journal-title":"J. Infect. Dis."},{"key":"775_CR161","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/j.cell.2015.07.043","volume":"162","author":"M Kanekiyo","year":"2015","unstructured":"Kanekiyo, M. et al. Rational design of an Epstein\u2013Barr virus vaccine targeting the receptor-binding site. Cell 162, 1090\u20131100 (2015).","journal-title":"Cell"},{"key":"775_CR162","doi-asserted-by":"crossref","first-page":"eabf3685","DOI":"10.1126\/scitranslmed.abf3685","volume":"14","author":"CJ Wei","year":"2022","unstructured":"Wei, C. J. et al. A bivalent Epstein\u2013Barr virus vaccine induces neutralizing antibodies that block infection and confer immunity in humanized mice. Sci. Transl. Med. 14, eabf3685 (2022).","journal-title":"Sci. Transl. Med."},{"key":"775_CR163","doi-asserted-by":"crossref","first-page":"285","DOI":"10.3390\/vaccines9030285","volume":"9","author":"X Cui","year":"2021","unstructured":"Cui, X. et al. Immunization with Epstein\u2013Barr virus core fusion machinery envelope proteins elicit high titers of neutralizing activities and protect humanized mice from lethal dose EBV challenge. Vaccines 9, 285 (2021).","journal-title":"Vaccines"},{"key":"775_CR164","doi-asserted-by":"crossref","first-page":"169","DOI":"10.3390\/vaccines8020169","volume":"8","author":"GM Escalante","year":"2020","unstructured":"Escalante, G. M. et al. A pentavalent Epstein\u2013Barr virus-like particle vaccine elicits high titers of neutralizing antibodies against Epstein\u2013Barr virus infection in immunized rabbits. Vaccines 8, 169 (2020).","journal-title":"Vaccines"},{"key":"775_CR165","doi-asserted-by":"crossref","first-page":"13105","DOI":"10.1128\/JVI.05598-11","volume":"85","author":"R Ruiss","year":"2011","unstructured":"Ruiss, R. et al. A virus-like particle-based Epstein\u2013Barr virus vaccine. J. Virol. 85, 13105\u201313113 (2011).","journal-title":"J. Virol."},{"key":"775_CR166","doi-asserted-by":"crossref","first-page":"5009","DOI":"10.1158\/1078-0432.CCR-14-1122-T","volume":"20","author":"GS Taylor","year":"2014","unstructured":"Taylor, G. S. et al. A recombinant modified vaccinia ankara vaccine encoding Epstein\u2013Barr Virus (EBV) target antigens: a phase I trial in UK patients with EBV-positive cancer. Clin. Cancer Res. 20, 5009\u20135022 (2014).","journal-title":"Clin. Cancer Res."},{"key":"775_CR167","first-page":"849","volume":"33","author":"Y Zeng","year":"2020","unstructured":"Zeng, Y. et al. LMP2-DC vaccine elicits specific EBV-LMP2 response to effectively improve immunotherapy in patients with nasopharyngeal cancer. Biomed. Env. Sci. 33, 849\u2013856 (2020).","journal-title":"Biomed. Env. Sci."},{"key":"775_CR168","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/annonc\/mdr341","volume":"23","author":"WK Chia","year":"2012","unstructured":"Chia, W. K. et al. A phase II study evaluating the safety and efficacy of an adenovirus-DeltaLMP1-LMP2 transduced dendritic cell vaccine in patients with advanced metastatic nasopharyngeal carcinoma. Ann. Oncol. 23, 997\u20131005 (2012).","journal-title":"Ann. Oncol."},{"key":"775_CR169","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1007\/s12094-019-02060-8","volume":"21","author":"CR Garcia","year":"2019","unstructured":"Garcia, C. R., Jayswal, R., Adams, V., Anthony, L. B. & Villano, J. L. Multiple sclerosis outcomes after cancer immunotherapy. Clin. Transl. Oncol. 21, 1336\u20131342 (2019).","journal-title":"Clin. Transl. Oncol."},{"key":"775_CR170","doi-asserted-by":"crossref","first-page":"eaau5612","DOI":"10.1126\/scitranslmed.aau5612","volume":"11","author":"TE Messick","year":"2019","unstructured":"Messick, T. E. et al. Structure-based design of small-molecule inhibitors of EBNA1 DNA binding blocks Epstein\u2013Barr virus latent infection and tumor growth. Sci. Transl. Med. 11, eaau5612 (2019).","journal-title":"Sci. Transl. Med."},{"key":"775_CR171","doi-asserted-by":"crossref","first-page":"101260","DOI":"10.1016\/j.coviro.2022.101260","volume":"56","author":"SS Soldan","year":"2022","unstructured":"Soldan, S. S., Messick, T. E. & Lieberman, P. M. Therapeutic approaches to Epstein\u2013Barr virus cancers. Curr. Opin. Virol. 56, 101260 (2022).","journal-title":"Curr. Opin. Virol."},{"key":"775_CR172","doi-asserted-by":"crossref","first-page":"2571","DOI":"10.1182\/blood-2006-01-024703","volume":"109","author":"SP Perrine","year":"2007","unstructured":"Perrine, S. P. et al. A phase 1\/2 trial of arginine butyrate and ganciclovir in patients with Epstein\u2013Barr virus-associated lymphoid malignancies. Blood 109, 2571\u20132578 (2007).","journal-title":"Blood"},{"key":"775_CR173","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1002\/ijc.29698","volume":"138","author":"KF Hui","year":"2016","unstructured":"Hui, K. F. et al. Inhibition of class I histone deacetylases by romidepsin potently induces Epstein\u2013Barr virus lytic cycle and mediates enhanced cell death with ganciclovir. Int. J. Cancer 138, 125\u2013136 (2016).","journal-title":"Int. J. Cancer"},{"key":"775_CR174","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/blood-2018-03-785931","volume":"131","author":"CM Bollard","year":"2018","unstructured":"Bollard, C. M. & Cohen, J. I. How I treat T-cell chronic active Epstein\u2013Barr virus disease. Blood 131, 2899\u20132905 (2018).","journal-title":"Blood"},{"key":"775_CR175","doi-asserted-by":"crossref","first-page":"242ra283","DOI":"10.1126\/scitranslmed.3008825","volume":"6","author":"A Papadopoulou","year":"2014","unstructured":"Papadopoulou, A. et al. Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT. Sci. Transl. Med. 6, 242ra283 (2014).","journal-title":"Sci. Transl. Med."},{"key":"775_CR176","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1002\/cncr.30541","volume":"123","author":"J Huang","year":"2017","unstructured":"Huang, J. et al. Epstein\u2013Barr virus-specific adoptive immunotherapy for recurrent, metastatic nasopharyngeal carcinoma. Cancer 123, 2642\u20132650 (2017).","journal-title":"Cancer"},{"key":"775_CR177","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.144624","volume":"5","author":"MP Pender","year":"2020","unstructured":"Pender, M. P. et al. Epstein\u2013Barr virus-specific T cell therapy for progressive multiple sclerosis. JCI Insight 5, e144624 (2020).","journal-title":"JCI Insight"},{"key":"775_CR178","doi-asserted-by":"crossref","first-page":"652811","DOI":"10.3389\/fneur.2021.652811","volume":"12","author":"ZA Ioannides","year":"2021","unstructured":"Ioannides, Z. A. et al. Sustained clinical improvement in a subset of patients with progressive multiple sclerosis treated with Epstein\u2013Barr virus-specific T cell therapy. Front. Neurol. 12, 652811 (2021).","journal-title":"Front. Neurol."},{"key":"775_CR179","doi-asserted-by":"crossref","first-page":"640935","DOI":"10.3389\/fimmu.2021.640935","volume":"12","author":"A Lutterotti","year":"2021","unstructured":"Lutterotti, A., Hayward-Koennecke, H., Sospedra, M. & Martin, R. Antigen-specific immune tolerance in multiple sclerosis-promising approaches and how to bring them to patients. Front. Immunol. 12, 640935 (2021).","journal-title":"Front. Immunol."},{"key":"775_CR180","doi-asserted-by":"crossref","first-page":"188ra175","DOI":"10.1126\/scitranslmed.3006168","volume":"5","author":"A Lutterotti","year":"2013","unstructured":"Lutterotti, A. et al. Antigen-specific tolerance by autologous myelin peptide-coupled cells: a phase 1 trial in multiple sclerosis. Sci. Transl. Med. 5, 188ra175 (2013).","journal-title":"Sci. Transl. Med."},{"key":"775_CR181","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1084\/jem.182.1.75","volume":"182","author":"BL McRae","year":"1995","unstructured":"McRae, B. L., Vanderlugt, C. L., Dal Canto, M. C. & Miller, S. D. Functional evidence for epitope spreading in the relapsing pathology of experimental autoimmune encephalomyelitis. J. Exp. Med. 182, 75\u201385 (1995).","journal-title":"J. Exp. Med."}],"container-title":["Nature Reviews Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00775-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00775-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T14:28:56Z","timestamp":1722868136000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41582-023-00775-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,9]]},"references-count":181,"alternative-id":["775"],"URL":"https:\/\/doi.org\/10.1038\/s41582-023-00775-5","relation":{},"ISSN":["1759-4758","1759-4766"],"issn-type":[{"value":"1759-4758","type":"print"},{"value":"1759-4766","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,9]]},"assertion":[{"value":"11 January 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.I.C. is named as an inventor on patent applications for Epstein\u2013Barr virus vaccines, which have been filed by the NIH. A.A. has received an honorarium as a speaker from Moderna. K.B. and C.M. declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}